XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)

Cohort A: Naïve (no irinotecan treatment before) postmenopausal female cancer patients. Inclusion criteria: 1. Malignant tumor confirmed by histology or cytology; 2. Postmenopausal women, after bilateral oophorectomy; age \> 60 years old, or age \< 60 years old with menopause for more than 1 year; 3. Age ≥ 18 years old, ≤ 75 years old; 4. ECOG score of the patient ≤ 2 points; 5. Never been treated with irinotecan; 6. Plan to receive at least 3 rounds of FOLFIRI chemotherapy determined by physicians; 7. Normal organ functions can meet the requirements for systemic chemotherapy: * Reserve functions of normal bone marrow: absolute neutrophil count (ANC) ≥ 1.5×109/L, PLT ≥ 100×109/L, hemoglobin ≥ 90 g/L; * Normal renal functions: serum creatinine ≤ 1.5 mg/dl (133 μmol/L) and/or creatinine clearance ≥ 60 ml/min; * Normal hepatic functions: total serum bilirubin level ≤ 1.5 times of the upper limit of normal value (ULN), serum aspartate aminotransferase (AST) \& alanine aminotransferase (ALT) ≤ 2.5 × ULN; If abnormal hepatic functions are caused by a potentially malignant tumor, and AST ＆ ALT ≤ 5 × ULN; 8. Patient is willing to participate and cooperate to complete the questions in the case report form; 9. Patient can understand and sign the informed consent form, is well compliant, and can be followed up. Cohort B: cancer patients who experienced irinotecan -induced diarrhea (grade \>2) Inclusion criteria: 1. Malignant tumor confirmed by histology or cytology; 2. Age ≥ 18 years old, ≤ 75 years old; 3. ECOG score of the patient ≤ 2 points; 4. Patients who have diarrhea worse than grade 2 due to irinotecan chemotherapy (the last dose of irinotecan is administered within 1 month); 5. Patients who plan to receive 3 rounds of FOLFIRI chemotherapy; 6. Normal organ functions can meet the requirements for systemic chemotherapy: * Reserve functions of normal bone marrow: absolute neutrophil count (ANC) ≥ 1.5×109/L, PLT ≥ 100×109/L, hemoglobin ≥ 90g/L; * Normal renal functions: serum creatinine ≤ 1.5mg/dl (133μmol/L) and/or creatinine clearance ≥ 60ml/min; * Normal hepatic functions: total serum bilirubin level ≤ 1.5 times of the upper limit of normal value (ULN), serum aspartate aminotransferase (AST) \& alanine aminotransferase (ALT) ≤ 2.5 × ULN; If abnormal hepatic functions are caused by a potentially malignant tumor, and AST ＆ ALT ≤ 5 × ULN; 7. Patient is willing to participate and cooperate to complete the questions in the case report form; 8. Patients can understand and sign the informed consent form, is well compliant, and can be followed up. Exclusion Criteria: 1. Patients with diagnosed depression, obsession or/and schizophrenia; 2. Patients with diagnosed inflammatory bowel diseases (including Crohn's disease, ulcerative colitis) 3. Patient with active tuberculosis and other uncontrolled infections; 4. Patient has previously received radiotherapy on the abdominal cavity and pelvic cavity; 5. Pregnant or lactating women; 6. Patient previously had or is now having thromboembolic (blood clotting) events.